Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance

doi:10.1007/s10555-024-10177-8

Review

. 2024 Mar 18.

doi: 10.1007/s10555-024-10177-8. Online ahead of print.

Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance

Shabnam Malik^{1

2}, Mohammed Sikander^{1

2}, Mohd Wahid³, Anupam Dhasmana^{1

2}, Maryam Sarwat⁴, Sheema Khan^{1

2}, Everardo Cobos⁵, Murali M Yallapu^{1

2}, Meena Jaggi^{1

2}, Subhash C Chauhan^{6

7}

Affiliations

¹ Department of Immunology and Microbiology, School of Medicine, Biomedical Research Building, University of Texas Rio Grande Valley, 5300 North L Street, McAllen, TX, 78504, USA.
² South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA.
³ Unit of Research and Scientific Studies, College of Nursing and Allied Health Sciences, University of Jazan, Jizan, Saudi Arabia.
⁴ Amity Institute of Pharmacy, Amity University, Uttar Pradesh, Noida, India.
⁵ Department of Medicine, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA.
⁶ Department of Immunology and Microbiology, School of Medicine, Biomedical Research Building, University of Texas Rio Grande Valley, 5300 North L Street, McAllen, TX, 78504, USA. Subhash.Chauhan@utrgv.edu.
⁷ South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA. Subhash.Chauhan@utrgv.edu.

PMID: 38498072
DOI: 10.1007/s10555-024-10177-8

Review

Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance

Shabnam Malik et al. Cancer Metastasis Rev. 2024.

. 2024 Mar 18.

doi: 10.1007/s10555-024-10177-8. Online ahead of print.

Authors

Affiliations

¹ Department of Immunology and Microbiology, School of Medicine, Biomedical Research Building, University of Texas Rio Grande Valley, 5300 North L Street, McAllen, TX, 78504, USA.
² South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA.
³ Unit of Research and Scientific Studies, College of Nursing and Allied Health Sciences, University of Jazan, Jizan, Saudi Arabia.
⁴ Amity Institute of Pharmacy, Amity University, Uttar Pradesh, Noida, India.
⁵ Department of Medicine, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA.
⁶ Department of Immunology and Microbiology, School of Medicine, Biomedical Research Building, University of Texas Rio Grande Valley, 5300 North L Street, McAllen, TX, 78504, USA. Subhash.Chauhan@utrgv.edu.
⁷ South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX, USA. Subhash.Chauhan@utrgv.edu.

PMID: 38498072
DOI: 10.1007/s10555-024-10177-8

Abstract

There has been a surge of interest in recent years in understanding the intricate mechanisms underlying cancer progression and treatment resistance. One molecule that has recently emerged in these mechanisms is MUC13 mucin, a transmembrane glycoprotein. Researchers have begun to unravel the molecular complexity of MUC13 and its impact on cancer biology. Studies have shown that MUC13 overexpression can disrupt normal cellular polarity, leading to the acquisition of malignant traits. Furthermore, MUC13 has been associated with increased cancer plasticity, allowing cells to undergo epithelial-mesenchymal transition (EMT) and metastasize. Notably, MUC13 has also been implicated in the development of chemoresistance, rendering cancer cells less responsive to traditional treatment options. Understanding the precise role of MUC13 in cellular plasticity, and chemoresistance could pave the way for the development of targeted therapies to combat cancer progression and enhance treatment efficacy.

Keywords: Cancer cell plasticity; Cancer stem cell; Drug resistance; EMT; MUC13; Metastasis; Mucin.

PubMed Disclaimer

Cited by

Breaking the Mucin Barrier: A New Affinity Chromatography-Mass Spectrometry Approach to Unveil Potential Cell Markers and Pathways Altered in Pseudomyxoma Peritonei.
Romero-Ruiz A, Granados-Rodríguez M, Bura FI, Valenzuela-Molina F, Rufián-Andújar B, Martínez-López A, Rodríguez-Ortiz L, Ortega-Salas R, Torres-Martínez M, Moreno-Serrano A, Castaño J, Michán C, Alhama J, Vázquez-Borrego MC, Arjona-Sánchez Á. Romero-Ruiz A, et al. Biol Proced Online. 2024 May 15;26(1):13. doi: 10.1186/s12575-024-00239-0. Biol Proced Online. 2024. PMID: 38750435 Free PMC article.

References

1. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed
1. Urruticoechea, A., Alemany, R., Balart, J., Villanueva, A., Viñals, F., & Capellá, G. (2010). Recent advances in cancer therapy: An overview. Current Pharmaceutical Design, 16, 3–10. https://doi.org/10.2174/138161210789941847 - DOI - PubMed
1. Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K. W. (2012). Cancer and radiation therapy: Current advances and future directions. International Journal of Medical Sciences, 9, 193–199. https://doi.org/10.7150/ijms.3635 - DOI - PubMed - PMC
1. Wang, X., Zhang, H., & Chen, X. (2019). Drug resistance and combating drug resistance in cancer. Cancer Drug Resist, 2, 141–160. https://doi.org/10.20517/cdr.2019.10 - DOI - PubMed - PMC
1. Longley, D. B., & Johnston, P. G. (2005). Molecular mechanisms of drug resistance. The Journal of Pathology, 205, 275–292. https://doi.org/10.1002/path.1706 - DOI - PubMed

Publication types

Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Springer

[1] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed

[2] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209–249. https://doi.org/10.3322/caac.21660 - DOI - PubMed

[3] Urruticoechea, A., Alemany, R., Balart, J., Villanueva, A., Viñals, F., & Capellá, G. (2010). Recent advances in cancer therapy: An overview. Current Pharmaceutical Design, 16, 3–10. https://doi.org/10.2174/138161210789941847 - DOI - PubMed

[4] Urruticoechea, A., Alemany, R., Balart, J., Villanueva, A., Viñals, F., & Capellá, G. (2010). Recent advances in cancer therapy: An overview. Current Pharmaceutical Design, 16, 3–10. https://doi.org/10.2174/138161210789941847 - DOI - PubMed

[5] Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K. W. (2012). Cancer and radiation therapy: Current advances and future directions. International Journal of Medical Sciences, 9, 193–199. https://doi.org/10.7150/ijms.3635 - DOI - PubMed - PMC

[6] Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K. W. (2012). Cancer and radiation therapy: Current advances and future directions. International Journal of Medical Sciences, 9, 193–199. https://doi.org/10.7150/ijms.3635 - DOI - PubMed - PMC

[7] Wang, X., Zhang, H., & Chen, X. (2019). Drug resistance and combating drug resistance in cancer. Cancer Drug Resist, 2, 141–160. https://doi.org/10.20517/cdr.2019.10 - DOI - PubMed - PMC

[8] Wang, X., Zhang, H., & Chen, X. (2019). Drug resistance and combating drug resistance in cancer. Cancer Drug Resist, 2, 141–160. https://doi.org/10.20517/cdr.2019.10 - DOI - PubMed - PMC

[9] Longley, D. B., & Johnston, P. G. (2005). Molecular mechanisms of drug resistance. The Journal of Pathology, 205, 275–292. https://doi.org/10.1002/path.1706 - DOI - PubMed

[10] Longley, D. B., & Johnston, P. G. (2005). Molecular mechanisms of drug resistance. The Journal of Pathology, 205, 275–292. https://doi.org/10.1002/path.1706 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance

Affiliations

Deciphering cellular and molecular mechanism of MUC13 mucin involved in cancer cell plasticity and drug resistance

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

Grants and funding

LinkOut - more resources

Full Text Sources

Abstract

Similar articles

Cited by

References

Publication types

Related information

Grants and funding

LinkOut - more resources

Full Text Sources